Protein tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin signaling, has become the intense pharmaceutical interest for treating type-2 diabetes over the past decade [4, 5]. This evidence concerns the gene PTPN1 and type 2 diabetes mellitus.